MaxCyte
Cell & Gene Therapy · Bioprocessing

MaxCyte: Funding & valuation

MaxCyte has $760k paid in by investors, lenders and donors.

Financials

Revenue of $33M in 2025. −14.5% on the year before. Net income −$44.6M.

$33MRevenue2025 · −14.5%
−$44.6MNet income2025 · −8.7%
$760kTotal raised
Venture - Series UnknownLatest round
Revenue by yearas filed, with the net income
2025$33Mnet income −$44.6M
2024$38.6Mnet income −$41.1M
2023$41.3Mnet income −$37.9M
2022$44.3Mnet income −$23.6M
2021$33.9Mnet income −$19.1M
2020$26.2Mnet income −$11.8M
2019$21.6Mnet income −$12.9M
Money by yearUSD, rounds and grants
2016$760k1 record
Largest rounds and grants
Sources: SEC

Money

MaxCyte has $760k paid in by investors, lenders and donors.

$760kPaid in
StagePaidSignedAnnouncedSourceFiledAnnouncedPress
Money in
Equity raised
Mar 2016 · Venture round
$760kPaid
People cost

MaxCyte filed a median H-1B wage of $118k in 2026.

$118kMedian H-1B wage, 20261 casesSource ↗
Median H-1B wage by role, 2026scale to $118k
Senior Electrical Engineer · 1$118k
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".